Ann‐Lii Cheng

机构：National Taiwan University, National Taiwan University Hospital · ORCID：0000-0002-9152-6512

发表论文 1253 篇 · 总被引 76430 次 · h-index 99

代表论文

• The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment (2025 · The Lancet · 被引 167)
• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 25)
• Nanotherapeutics for microenvironment modulation and immune homeostasis in periodontitis treatment (2025 · Biomaterials · 被引 11)
• LBA50 IMbrave152/SKYSCRAPER-14: A phase III study of first-line tiragolumab (tira) + atezolizumab (atezo) + bevacizumab (bev) vs placebo (pbo) + atezo + bev for patients (pts) with untreated locally advanced or metastatic hepatocellular carcinoma (HCC) (2025 · Annals of Oncology · 被引 4)
• TACOS: Open Tagging and Comparative Scoring for Instruction Fine-Tuning Data Selection (2025 · arXiv (Cornell University) · 被引 1)
• Lenvatinib Versus Sorafenib in First-Line Treatment of Older Patients With Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial (2026 · Liver Cancer)